Oncology

Circulating tumour DNA sequencing to determine therapeutic response and identify tumour heterogeneity in patients with paediatric solid tumours | Stankunaite R, et al | European Journal of Cancer | Feb. 2022

By nonacus-developer / August 25, 2023 / Comments Off on Circulating tumour DNA sequencing to determine therapeutic response and identify tumour heterogeneity in patients with paediatric solid tumours | Stankunaite R, et al | European Journal of Cancer | Feb. 2022

Stankunaite R, George SL, Gallagher L, Jamal S, Shaikh R, Yuan L, et al. Circulating tumour DNA sequencing to determine therapeutic response and identify tumour heterogeneity in patients with paediatric solid tumours. European Journal of Cancer. 2022;162:209-20. Nonacus products: Oncology Objective: Clinical diagnostic sequencing of circulating tumour DNA (ctDNA) is well advanced for adult patients,…

Read More

Urine DNA for monitoring chemoradiotherapy response in muscle-invasive bladder cancer: a pilot study | Gordon NS, et al | BJU international | Jan. 2022

By nonacus-developer / August 25, 2023 / Comments Off on Urine DNA for monitoring chemoradiotherapy response in muscle-invasive bladder cancer: a pilot study | Gordon NS, et al | BJU international | Jan. 2022

Gordon NS, Baxter LA, Goel A, Arnold R, Kaur B, Liu W, et al. Urine DNA for monitoring chemoradiotherapy response in muscle-invasive bladder cancer: a pilot study. BJU International. 2022;129(1):32-4. Nonacus products: Oncology Overview: Accumulating evidence implies the utility of DNA-based urine biomarkers for initial detection of bladder cancer (BC) and surveillance of non-muscle-invasive BC.…

Read More

PF513 mutations affecting the CREBBP hat domain predict response to MTOR inhibitors Everolimus and Temsirolimus in relapsed/refractory follicular lymphoma | Kumar E, et al | HemaSphere | Jun. 2019

By nonacus-developer / August 25, 2023 / Comments Off on PF513 mutations affecting the CREBBP hat domain predict response to MTOR inhibitors Everolimus and Temsirolimus in relapsed/refractory follicular lymphoma | Kumar E, et al | HemaSphere | Jun. 2019

Kumar E, Korfi K, Bewicke-Copley F, Witzig T, Leukam M, Ansell S, Scott J, Rallis K, Clear A, Efeyan A, Calaminici M. PF513 mutations affecting the crebbp hat domain predict response to motor inhibitors everolimus and temsirolimus in relapsed/refractory follicular lymphoma. HemaSphere. 2019;3(S1):209. Nonacus products: Oncology Abstract With an expanding array of novel treatment options…

Read More

Whole-genome sequencing of single circulating tumor cells from neuroendocrine neoplasms | Childs A, et al | Endocrine-Related Cancer | Sep. 2021

By nonacus-developer / August 25, 2023 / Comments Off on Whole-genome sequencing of single circulating tumor cells from neuroendocrine neoplasms | Childs A, et al | Endocrine-Related Cancer | Sep. 2021

Childs A, Steele CD, Vesely C, Rizzo FM, Ensell L, Lowe H, et al. Whole-genome sequencing of single circulating tumor cells from neuroendocrine neoplasms. Endocrine-Related Cancer. 2021;28(9):631-44. Nonacus Products: Oncology Abstract Single-cell profiling of circulating tumor cells (CTCs) as part of a minimally invasive liquid biopsy presents an opportunity to characterize and monitor tumor heterogeneity…

Read More

Utility of circulating tumor DNA for detection and monitoring of endometrial cancer recurrence and progression | Moss EL, et al | Cancers | Aug. 2022

By nonacus-developer / August 25, 2023 / Comments Off on Utility of circulating tumor DNA for detection and monitoring of endometrial cancer recurrence and progression | Moss EL, et al | Cancers | Aug. 2022

Moss EL, Gorsia DN, Collins A, Sandhu P, Foreman N, Gore A, Wood J, Kent C, Silcock L, Guttery DS. Utility of circulating tumor DNA for detection and monitoring of endometrial cancer recurrence and progression. Cancers. 2020 ;12(8):2231. Nonacus Products: Germline Abstract Despite the increasing incidence of endometrial cancer (EC) worldwide and the poor overall survival…

Read More

Circulating cell-free DNA for prognostication and disease surveillance in adrenocortical carcinoma | Lippert J, et al | European Journal of Endocrinology | Mar. 2024

By nonacus-developer / August 25, 2023 / Comments Off on Circulating cell-free DNA for prognostication and disease surveillance in adrenocortical carcinoma | Lippert J, et al | European Journal of Endocrinology | Mar. 2024

Childs A, Steele CD, Vesely C, Rizzo FM, Ensell L, Lowe H, et al. Whole-genome sequencing of single circulating tumor cells from neuroendocrine neoplasms. Endocrine-Related Cancer. 2021;8(9):631-44 Nonacus Products: Germline Background Adrenocortical Carcinoma (ACC) is a rare aggressive cancer with a heterogeneous behaviour. Disease surveillance relies on frequent imaging, which has limited sensitivity and results in…

Read More

Targeted deep sequencing of urothelial bladder cancers and associated urinary DNA: a 23-gene panel with utility for non-invasive diagnosis and risk stratification | Ward DG, et al | BJU International | Sep. 2019

By nonacus-developer / August 25, 2023 / Comments Off on Targeted deep sequencing of urothelial bladder cancers and associated urinary DNA: a 23-gene panel with utility for non-invasive diagnosis and risk stratification | Ward DG, et al | BJU International | Sep. 2019

Ward DG, Gordon NS, Boucher RH, Pirrie SJ, Baxter L, Ott S, et al. Targeted deep sequencing of urothelial bladder cancers and associated urinary DNA: a 23‐gene panel with utility for non‐invasive diagnosis and risk stratification. BJU International. 2019;124(3):532-44. Nonacus products: Oncology Objectives To develop a focused panel of somatic mutations (SMs) present in the majority…

Read More